These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 1895414)

  • 1. Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients.
    Stief CG; Wetterauer U; Schaebsdau FH; Jonas U
    J Urol; 1991 Oct; 146(4):1010-4. PubMed ID: 1895414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction.
    Djamilian M; Stief CG; Kuczyk M; Jonas U
    J Urol; 1993 May; 149(5 Pt 2):1296-8. PubMed ID: 8479019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
    Waldhauser M; Schramek P
    J Urol; 1988 Sep; 140(3):525-7. PubMed ID: 3045341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracavernous calcitonin gene-related peptide plus prostaglandin E1: possible alternative to penile implants in selected patients.
    Truss MC; Becker AJ; Thon WF; Kuczyk M; Djamilian MH; Stief CG; Jonas U
    Eur Urol; 1994; 26(1):40-5. PubMed ID: 7925528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penile pharmacological duplex ultrasonography: a dose-effect study comparing papaverine, papaverine/phentolamine and prostaglandin E1.
    Meuleman EJ; Bemelmans BL; Doesburg WH; van Asten WN; Skotnicki SH; Debruyne FM
    J Urol; 1992 Jul; 148(1):63-6. PubMed ID: 1613884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 therapy for impotence, comparison with papaverine.
    Earle CM; Keogh EJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR; Glatthaar C
    J Urol; 1990 Jan; 143(1):57-9. PubMed ID: 2294263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the feline erection model.
    Champion HC; Wang R; Santiago JA; Murphy WA; Coy DH; Kadowitz PJ; Hellstrom WJ
    J Androl; 1997; 18(5):513-21. PubMed ID: 9349749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atropine role in the pharmacological erection test: study of 228 patients.
    Sogari PR; Telöken C; Souto CA
    J Urol; 1997 Nov; 158(5):1760-3. PubMed ID: 9334595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved vasoactive drug combination for a pharmacological erection program.
    Bennett AH; Carpenter AJ; Barada JH
    J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients].
    Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
    Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.